Andrew J. Souers
AbbVie (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Cell death mechanisms and regulation, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors(2017)893 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)(2015)427 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models(2016)308 cited
- → The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma(2013)290 cited
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208(2013)
- → Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction(2020)177 cited
- → β-Turn mimetic library synthesis: scaffolds and applications(2001)158 cited